Clinical studies confirm that postoperative adjuvant chemotherapy could significantly reduce mortality rate of patients with the operable breast cancer and improve surviral rate. At present, adjuvant chemotherapy of breast cancer is developing for the direction of high specificity, more efficiency and low toxicity. Individualized and standardized comprehensive treatment which based on molecular genetic analysis is the direction of adjuvant chemotherapy of breast cancer.

Mitochondrial DNA (mtDNA) is more susceptible to oxidative damage and has a higher mutation rate compared with nuclear DNA due to the absence of protective histone proteins and imperfect repair system.Somatic alterations in mtDNA have been proposed to contribute to initiation and progression of human cancer in previous researches.However,the role of these mtDNA alterations in gastric cancer progression remains unclear.Point mutations and mtDNA content alterations are the two most common mtDNA alterations that result in mitochondrial dysfunction in gastric cancers.Identifing somatic mtDNA alterations in gastric cancers as well as their association with the clinicopathological parameters of gastric cancer,and exploring the causative factors of the somatic mtDNA alterations in cancer progression have been a new direction of gastric cancer research in recent years.

As one of the treatment options for early stage NSCLC,stereotactic body radiation therapy (SBRT)is mainly applied to the inoperable patients.Compared with small doses of traditional fractionated radi-ation treatment,SBRT are taken a single high dose of radiation.A large body of experience has been accumula-ted over the years and the mathematical model to describe survival in high dose range typically used in SBRT and the best dose of segmentation model were focused on,but there has not yet reached a consensus.Studies show that SBRT has certain advantages in local control ratio and adverse reaction compared with traditional radiotherapy,which can be used in operable patients in the future.

Neoadjuvant systemic therapy for breast cancer patients means systemic treatments before operations.Combination chemotherapy,endocrine therapy and targeted therapy before operation can degrade the tumor staging and increase the breast-conserving rates.Neoadjuvant chemotherapy has been accepted as one of the standard therapies for patients with locally advanced breast cancers.In the neoadjuvant setting,the studies about the use of aromatase inhibitors and trastuzumab in selected patients have also made great progresses.

Breast cancer stem cells (BCSCs) play an important role in radiation and chemotherapy resistance.Different cancer subtypes mean different BCSCs.Inhibitors for BCSCs are gradually explored in clinical trials.Circulating tumor cells (CTCs) are crucial process to tumor metastasis.CTCs seem to be associated with stem cell phenotype.Therefore,further research for BCSCs will enable us to achieve improvement of their clinical application.

The National Surgical Adjuvant Breast and Bowel Project (NSABP) is a clinical trials cooperative group supported by the National Cancer Institute (NCI).The NSABP has conducted clinical trials in breast and colorectal cancer for nearly 40 years,many of which have greatly improved the therapies in breast and colorectal cancers.There have been some new advances on new adjuvant chemotherapy regimens,targeted therapy,adjuanvt and neoadjuvant therapies for rectal cancer in recent 5 years.

Triple negative breast cancer (TNBC) is a special subgroup of breast cancer with more aggressive biological behavior and clinicopathological characteristics,and the therapy of TNBC has always been the research difficulty and hot spot.Currently,surgery and adjuvant radiotherapy are still the main method in local treatment,amd the research of traditional chemotherapy and targeted therapy have been made some progress.Meanwhile,new drugs continuously appear in recent years.

Colorectal Neoplasms ; diagnosis ; metabolism ; Humans ; Metabolomics

Objective To study the presence of drug resistant mutations of protease and reverse transcriptase among human immunodeficiency virus (HIV)-1 strains isolated from treatment naive HIV/ acquired immune deficiency syndrome (AIDS) patients in Heilongjiang Province of China and to provide the baseline data for starting antiretroviral therapy in this area. Methods The protease and reverse transcriptase gene sequences were amplified by nested-polymerase chain reaction (PCR) and then sequenced. The results were compared to the subtype B consensus amino acid sequence and analyzed with Stanford HIV-db drug resistance sequence interpretation. Results The results showed that HIV strains from 49 patients were classified as subtype B'. No primary mutations associated with protease inhibitor were detected. Some secondary mutations associated with protease inhibitor were detected, which included V77I(91.5%), L63P(76.6%), I93L(74.5%), E35D(61.7%), R57K (19.1%), R41K(10.6%), A71V(8.5%), M36I(8.5%), L10I(6.4%), D60E(6.4%), L89M (4.2%) and G16E(2. 1%). Only one case had a primary mutation M184I that was associated with resistance to reverse transcriptase inhibitors. However, many secondary mutations associated with resistance to reverse transcriptase inhibitors were found, including I135L/T/R/V(81.8%), V106I(22.7%), V179D/E(11.4%), R211K(9.1%), L214F(4.5%), V189I(4.5%) and V108I(2. 3%).Conclusions The prevalence of genotypic anti-HIV drug resistance is very low in treatment naive HIV/AIDS patients in Heilongjiang Province. However, closely monitoring on drug resistance mutation is very important for preventing the development and prevalence of multi-drug resistant or cross drug resistant HIV.

Objective To investigate the effect ot ionizing radiation (IR) on the expressions of HMGB1 in the radiation-sensitive and radiation-resistant human cervical cancer cells and to analysis the role of HMGB1 in the regulation of radiosensitivity.Methods Human cervical cancer cells HeLa and its radioresistant strain HeLaR cells were irradiated with different doses of X-rays.The cells were collected at different time points after irradiation.The expressions of protein and mRNA of HMGB1 were detected by Western blot and real-time quantitative PCR.Results At the protein level,the expression of HMGB1 in HeLaR cells was significantly reduced at 6-36 h after 2,5 and 10 Gy X-ray irradiation (t =3.574-9.754,P ＜0.05),and then it was recovered to the control level at 48 h after IR.On the contrary,the expression of HMGB1 in HeLa cells was significantly increased at 6,12,48 h after 2 Gy IR (t =3.945-4.864,P＜0.05),at 6,36,48hafter5 GyIR (t=-2.875-3.295,P＜0.05),and at 36,48 h after 10 Gy IR (t =-4.480,-4.517,P ＜ 0.05).At mRNA level,the trend of HMGB1 expression alteration was consistent with that of protein expression.Conclusions The changes of HMGB1 expression can be differently induced by X-rays in the human cervical cancer radiation-sensitivity cells and radiation-resistant cells.HMGB1 may be involved in the radioresistance of human cervical cancer.